Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Hjardem, E., Ostergaard, M., Podenphant, J., Tarp, U., Andersen, L. S., Bing, J., Peen, E., Lindegaard, H. M., Ringsdal, V. S., Rodgaard, A., Skot, J., Hansen, A., Mogensen, H. H., Unkerskov, J., HetlVolume:
66
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/ard.2006.054742
Date:
March, 2007
File:
PDF, 221 KB
english, 2007